Pandemic Expected To Drive Rolling Review Upsurge At EMA
Agency Will Demand 50% of Full MAA Fee Upfront
Executive Summary
The European Medicines Agency is anticipating greater use of its rolling review process during the coronavirus pandemic. Companies who use it will be asked to pay upfront half of what they would pay for a full marketing application.
You may also be interested in...
Two In Running For Top Job At EMA
A new executive director will be chosen for the European Medicines Agency on 25 June. The agency's management board has two candidates from which to choose.
EU Clinical Trials Regulation To Apply From December 2021
Executive Summary: The European Medicines Agency’s management board has decided on December 2021 as the go-live date for the EU Clinical Trials Information System. It will also meet later this month to elect the EMA’s new executive director to succeed Guido Rasi.
Gilead Files For Remdesivir Approval In EU
The much-anticipated EU filing for Gilead’s COVID-19 treatment is being reviewed quickly by the European Medicines Agency.